Navigation Links
InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO

InVitria’s BioProcess Theater presentation, “New Strategies for Optimizing CHO Performance,” to feature new supplement for CHO cell culture optimization called ZAP-CHO during BIO 2009 International Convention in Atlanta, GA. 

Fort Collins, CO May 19, 2009 / b3c newswire / – InVitria’s Director of Cell Culture, Dr. Steve Pettit, will present the performance enhancing features of ZAP-CHO, a new media component for Chinese hamster ovary (CHO) cell culture, at 3:30 pm on Wednesday, May 20, 2009 as part of BioProcess International’s BioProcess Theatre, a venue employed to facilitate the sharing of advances and discoveries in the biopharmaceutical sector.  

ZAP-CHO, a new product from InVitria, enhances performance of mammalian cell culture including improved cell growth and antibody production. It achieves these performance advantages in chemically defined media that are completely free of animal components. Previously, the performance seen with ZAP-CHO was only possible by utilizing animal components such as FBS (fetal bovine serum), BSA (bovine serum albumin) or plasma-derived HSA (human serum albumin) in cell culture media.

“Our team of scientists has developed supplements that not only meet the regulatory requirements of researchers using hybridoma and CHO cell culture, but it exceeds their performance expectations as well,” said Dr. Pettit. “InVitria products have been utilized by customers to successfully achieve greater cell productivity and growth; faster cell doublings; and improved consistency.”

InVitria’s other leading cell culture media supplements will also be part of the BIO Process Product Zone exhibition in Booth #5120 within the BIO 2009 International Convention from May 19-21.  These supplements include:
* Albumin-DX—whether you have problems with non-specific binding, biomarker stability, consistency or regulatory requirements, Albumin-DX was designed to answer the most difficult assay challenges.
* Cellastim—Cellastim outperforms plasma-derived albumin, bovine serum albumin and other sources of recombinant albumin.
* Lacromin—Lacromin is a CHO growth-factor that outperforms insulin and IGF-1.

About InVitria -

InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture products and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

Erik H. Vogel
Marketing Manager
Phone: 1-800-916-8311

b3c newswire

Related biology news :

1. InVitria Announces Launch of Recombinant Albumin for Diagnostics
2. Unveiling the structure of microcrystals
3. EC unveils new EU maritime policy
4. Scientists unveil structure of molecular target of many drugs
5. Tumor genome analysis unveils new insights into lung cancer
6. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
7. Research unveils new hope for deadly childhood disease
8. LTER unveils a new decadal science plan
9. Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition
10. Unveiling the underwater ways of the white shark
11. Washington University unveils draft sequence of corn genome
Post Your Comments:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology: